Potential muscle loss : GLP-1s can cause lean mass loss alongside fat loss
In real-world data, GLP-1RAs differ in clinical indications, uptake over time, adherence rate, typical treatment duration, dose escalation, and patient selection, all of which can introduce residual confounding and channeling bias ( Notably, the observed reductions in the odds of substance use disorders, including a 74% decrease in the odds of AUD, a 69% reduction for OUD, a 68% reduction for NUD, and a 75% reduction for CUD, among GLP-1 RA users were consistent with emerging preclinical and clinical studies showing that GLP-1 RA modulates reward pathways in the brain to reduce SUD ( 4.1 Strengths and limitations of the study This study has several notable strengths
By activating these receptors in the central nervous system, PT-141 promotes increased release of neurotransmitters such as dopamine, norepinephrine, and oxytocin, thereby enhancing sexual desire and arousal
Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease
When Medicare, Medicaid recipients will see discounts As early as May, GLP-1 coverage for beneficiaries of Medicaid joint federal-state health programs for people of all ages with limited incomes will begin, the Centers for Medicare and Medicaid Services (CMS) said in late 2025